Form 4: Dexcom COO Boosts Stake with $1M Stock Purchase

Dexcom's President & COO, Jacob Steven Leach, acquired 18,200 shares of common stock for over $1 million through open market purchases.

Summary

• Jacob Steven Leach, President & COO of Dexcom Inc. (DXCM), reported the acquisition of 18,200 shares of common stock.
• The transactions occurred on November 10, 2025, and were executed under a Rule 10b5-1 trading plan.
• A total of 15,700 shares were purchased at a weighted average price of $54.977 per share, totaling approximately $863,140.90.
• An additional 2,500 shares were purchased at a weighted average price of $55.4252 per share, totaling approximately $138,563.00.
• The total value of the shares acquired is approximately $1,001,703.90.
• Following these transactions, Leach directly beneficially owns 331,697 shares of common stock, which includes 84,537 unvested restricted stock units (RSUs).
• Indirect beneficial ownership amounts to 47,296 shares held by the Gregg Family Grandchildren's Trust, where Leach's spouse is a trustee.
• The unvested RSUs include grants from March 8, 2023, March 8, 2024, and two grants from March 8, 2025, with vesting periods extending through March 8, 2026, March 8, 2027, and March 8, 2028.

Sentiment

Score: 8

Explanation: The significant open market purchase by a high-ranking executive like the President & COO indicates strong internal confidence in the company's current valuation and future prospects, which is generally viewed positively by the market.

Positives

• The President & COO's significant open market purchase of over $1 million in company stock signals strong management confidence in Dexcom's future prospects and valuation.
• The transactions were made pursuant to a Rule 10b5-1 plan, indicating a pre-planned investment strategy rather than a reaction to immediate market conditions.

Related Party Transactions

• Indirect beneficial ownership of 47,296 shares held by the Gregg Family Grandchildren's Trust, with the reporting person's spouse serving as a trustee.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
• Increased insider ownership aligns management's interests more closely with those of long-term shareholders.

Next Steps

• Continued vesting of restricted stock units through March 8, 2028, as per the established schedules.

Key Dates

Recommendation

The President & COO's substantial open market purchase of over $1 million in company stock, executed under a Rule 10b5-1 plan, is a strong indicator of management's belief in the company's intrinsic value and future growth trajectory. Such insider buying often precedes positive company performance and suggests that the executive views the stock as undervalued or poised for appreciation. This action signals confidence to the market and aligns executive interests with shareholder returns, making it a compelling reason for investors to consider a 'buy' position.

Keywords

Dexcom, DXCM, Insider Trading, Stock Purchase, Form 4, Jacob Steven Leach, COO, Beneficial Ownership, Rule 10b5-1